Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian hypertension education program

Journal of Hypertension

Volumn 21, Issue 8, 2003, Pages 1591-1597

  Campbell, Norman R C ^a,c   McAlister, Finlay A ^b   Brant, Rollin ^c   Levine, Mitch ^d   Drouin, Denis ^e   Feldman, Ross ^f   Herman, Robert ^a   Zarnke, Kelly ^g  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^e Maladies Chroniques   (Canada)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Antihypertensive drug; Education; High blood pressure; Hypertension; Hypertension control; Implementation

Indexed keywords

ACEBUTOLOL; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; METOLAZONE; METOPROLOL; NADOLOL; NITRIC ACID DERIVATIVE; PINDOLOL; PROPRANOLOL; SOTALOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CORONARY ARTERY DISEASE; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0041736468     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200308000-00025     Document Type: Article

References (30)

1. Murray CJLM, Lopez AD. Evidence-based health policy - lessons from the global burden of disease study. Science 1996; 274:740-743.
2. Vasan R, Beiser A, Seshadri S Larson M, Kannel W D'Agostino R, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA 2002; 287:1003-1010.
3. Banegas JR, Rodriguez-Artalejo F, de la Cruz Troca JJ, Guallar-Castillon P, del Rey Calero J. Blood pressure in Spain. Distribution, awareness, control and benefits of a reduction in average pressure. Hypertension 1998; 32:998-1002.
4. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid? J Hum Hypertension 1997; 11:213-220.
5. Khan N, Chockalingam A, Campbell NRC. Lack of control of high blood pressure and treatment recommendations in Canada. Can J Cardiol 2002; 18:657-661.
6. Joffres MR, Hamet P, MacLean DR, L'Italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. AJH 2001; 14:1099-1105.
7. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16:747-752.
8. O'Donnell C, Kannel W. Cardiovascular risks of hypertension: Lessons from observational studies. J Hypertens 1998; 16(suppl 6):S3-S7.
9. Levy D, Larson M, Vasan R, Kannal W, Ho K. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
10. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA 1996; 275:1571-1576.
11. World Health Organization. The world health report 2002. Geneva, Switzerland: World Health Organization; 2002.
12. Chockalingam A, Campbell N, Ruddy T, Taylor G, Steward P. National high blood pressure prevention and control strategy. Can J Cardiol 2000; 16:1087-1093.
13. Zarnke KB, Campbell NRC, McAlister FA, Levine M. A novel process for updating recommendations for managing hypertension: Rationale and methods. Can J Cardiol 2000; 16:1094-1102.
14. Campbell NRC, Nagpal S, Drouin D. Implementing hypertension recommendations. Can J Cardiol 2001; 17:851-853.
15. The Canadian Hypertension Recommendations Working Group. The 2001 Canadian Hypertension Recommendations - What is new and what is old but still important. Can J Cardiol 2002; 18:591-596.
16. Campbell NRC, Drouin D, Feldman RD. The 2001 Canadian hypertension recommendations: take-home messages. CMAJ 2002; 167:661-668.
17. Zarnke KB, McAlister FA, Campbell NRC, Levine M, Schiffrin E, Grover S, et al. The 2001 Canadian recommendations for the management of hypertension: Part one - Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol 2002; 18:604-624.
18. McAlister F, Zarnke K, Campbell NRC, Feldman R, Levine M, Mahon J, et al. The 2001 Canadian recommendations for the management of hypertension: Part two - Therapy. Can J Cardiol 2002; 18:625-641.
19. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2002; 356:359-365.
20. Hansson L, Zanchetti A, Carson DS, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
21. Lewis E, Hunsciker L, Clarke W, Berl T, Pohl M, Lewis J, et al. Reno protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358:1033-1041.
23. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting - enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
24. Brenner B, Cooper M, Zeeuw D, Keane W, Mitch W, Parving H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
25. Brophy JM, Joseph L. Rouleau JL. β-Blockers in congestive heart failure. Ann Int Med 2001; 134:569-572.
26. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83:1A-38A.
27. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. NEJM 2000; 342:145-153.
28. Wielgosz A, Arango M, Carew M, Ferguson A, Johansen H, Nair C, et al. (editors). The changing face of heart disease and stroke in Canada 2000. Ottawa: Heart and Stroke Foundation of Canada; 1999.
29. Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ 2002; 166:1039-1040.
30. Lenfant C. Reflections on Hypertension Control Rates. Arch Intern Med 2002; 162:131-132.